#United States #Cambridge #Ovarian Cancer #Factor Bioscience #iMacrophages

Unveiling Innovation in Cancer Treatment: Factor Bioscience at ISCT 2026

Factor Bioscience Inc., a pioneering biotechnology company based in Cambridge, Massachusetts, is set to showcase its innovative research at the upcoming International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting. This prestigious event will take place in Dublin, Ireland, from May 6-9, 2026. The highlight of Factor Bioscience's presentation will be its promising engineered iMacrophages, specifically FACT-112, designed to combat ovarian cancer.

A Breakthrough in Gene-Editing Technology

Founded in 2011, Factor Bioscience has been on the cutting edge of biotechnology, leveraging its patented gene-editing platform to develop life-saving cell and gene therapies. The company aims to revolutionize the treatment of various cancers by utilizing immune system capabilities to fight tumors. The focus on ovarian cancer, known for its challenging prognosis, underscores Factor's commitment to addressing urgent medical needs.

Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor Bioscience, expressed excitement about sharing the latest pre-clinical data at the ISCT conference. He stated, “The remarkable anti-tumor activity of our engineered iMacrophages, shown in vivo, marks a significant achievement for our company and illustrates our dedication to transforming advanced science into practical therapies.”

FACT-112: The Engineered iMacrophage Program

The spotlight will be on the FACT-112 program, which involves IL12-expressing iMacrophages engineered to enhance immune responses against solid tumors. Ian Hay, the company’s Associate Director of Cell Engineering, will lead the presentation titled “iPSC-Derived Macrophages Engineered to Express IL-12 Modulate the Tumor Microenvironment and Support T Cell Lysis of Ovarian Cancer Models”. This presentation will detail how these engineered macrophages can reprogram the immunosuppressive environment of ovarian tumors, empowering the immune system to reject tumor cells effectively.

The pre-clinical data indicates a significant capacity for these modified macrophages to alter the tumor landscape, enhancing T cell response and potential tumor rejection. This is particularly vital for patients afflicted by solid tumors, who often face limited treatment options.

Looking Ahead: Potential Clinical Applications

Factor Bioscience's research is poised to pave the way for clinical applications that could provide new hope for patients with ovarian cancer and possibly other solid tumors. As they prepare for this notable presentation, the anticipation surrounding FACT-112 is growing, signaling a new frontier in cancer treatment. The company emphasizes the necessity of translating these research findings into safe and effective therapeutic strategies.

To learn more about Factor Bioscience and their cutting-edge research, please visit their official website at www.factorbio.com. For those attending the ISCT 2026 Annual Meeting, be sure to participate in the Immunotherapy Oral Presentation Session on May 6, where Factor Bioscience's latest innovations will be unveiled.

Conclusion

Factor Bioscience is at the forefront of transforming cancer treatment through innovative research and technology. The upcoming presentation of FACT-112 at ISCT 2026 represents not just a company milestone, but also the potential for significant advancements in the way we approach the treatment of malignancies like ovarian cancer. By harnessing the body’s immune mechanism in novel ways, Factor Bioscience exemplifies the future of therapeutic developments in oncology.